Login | Register

(VELA) Study of BLU-222 in Advanced Solid Tumors | Identifier: NCT05252416

Clinical trials are currently being offered at the University of Arkansas for Medical Sciences (UAMS).

Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.

Study Contact:
Blueprint Medicines